Ani Pharmaceuticals, Inc. · NASDAQ:ANIP

Ani Pharmaceuticals — Investor Presentation (January 2024)

18 slides from Ani Pharmaceuticals's investor presentation, Jan 8, 2024

  1. Slide 1: January 2024

    © 2023 ANI Pharmaceuticals, Inc. 1 January 2024

  2. Slide 2: Disclaimer

    © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statemen

  3. Slide 3: Rare Disease, Generics and Established Brands drive robust profitable growth

    © 2023 ANI Pharmaceuticals, Inc. 3 ANI Pharmaceuticals: Rare Disease, Generics and Established Brands businesses drive robust profitable growth Key Growth Drivers Rare Disease business with lead asset Purified Cortrophin Gel (PCG) and expansion through M&A Established Brands Generics with enhanced R

  4. Slide 4: Q3 2023: Achieved record financial results

    © 2023 ANI Pharmaceuticals, Inc. 4 Q3 2023: Achieved record financial results Q3 Revenues $132M 57% YoY Q3 Diluted non-GAAP EPS(1) $1.27 119% YoY Q3 Cortrophin Revenues $30M 136% YoY Q3 Adj. Non-GAAP EBITDA(1) $36M 98% YoY Year-to-Date Cash Flow from Operations(2) $74M Q3 Generic, Established Brands

  5. Slide 5: Raised full year 2023 guidance for third quarter in a row

    © 2023 ANI Pharmaceuticals, Inc. 5 Raised full year 2023 guidance for third quarter in a row (1) Adjusted Non-GAAP Gross Margin, Adjusted non-GAAP EBITDA, and Adjusted Non-GAAP Diluted EPS are non-GAAP financial measures. Metric ($ millions except per share amounts) Revised Full Year 2023 Guidance P

  6. Slide 6: Revenue growth driven by momentum across Rare Disease, Generics and Established Brands

    © 2023 ANI Pharmaceuticals, Inc. 6 Revenue growth driven by momentum across Rare Disease, Generics and Established Brands Revenues ($ million) 216 42 275 $- 2021 2022 $368-$371 $100-$107 2023E Generics, Est. Brands, Royalties, and Other Rare Disease $216 $316 $468-$478(1) +48%(2) 140-157% 34-35% Not

  7. Slide 7: Profitability driven by gross profit pull through and leveraging of Rare Disease infrastructure

    © 2023 ANI Pharmaceuticals, Inc. 7 Profitability driven by gross profit pull through and leveraging of Rare Disease infrastructure (1) Guidance shared at 3rd quarter earnings call (2) CAGR is calculated based on midpoint Adjusted Non-GAAP Gross-Margin ($ million) Adjusted Non-GAAP EBITDA(1) ($ milli

  8. Slide 8: Rare Disease: ANI's primary growth engine accelerating with lead asset

    © 2023 ANI Pharmaceuticals, Inc. 8 $17.6 $16.3 $24.3 $29.7 Rare Disease: ANI’s primary growth engine accelerating with lead asset Purified Cortrophin Gel (PCG) as foundation Continued strong momentum with record number of new patient starts and new cases initiated in Q3’23 • Grew all targeted specia

  9. Slide 9: ACTH Class has shown year-over-year quarterly unit growth for six consecutive quarters

    © 2023 ANI Pharmaceuticals, Inc. 9 ACTH Class has shown year-over-year quarterly unit growth for six consecutive quarters since Cortrophin launch Source: IQVIA ACTH Units – Year-over-Year Change From Q2 2022 to Q3 2023, the ACTH category has demonstrated six consecutive quarters of growth year-over-

  10. Slide 10: Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A

    © 2023 ANI Pharmaceuticals, Inc. 10 Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A Assets’ patent protection profile Assets’ peak year revenue forecast Priority 1: Rare disease opportunities in priority therapeutic areas for ANI, specifically Nephrology, Neu

  11. Slide 11: Superior R&D capabilities and operational excellence driving growth in Generics

    © 2023 ANI Pharmaceuticals, Inc. 11 Superior R&D capabilities and operational excellence driving growth in Generics Superior pipeline and new product launch execution • Increased R&D investment with focus on niche opportunities • Filed six new ANDAs in 2023 and three 505(b)2 NDA applications • Retai

  12. Slide 12: U.S.-based manufacturing footprint; strong GMP track record

    © 2023 ANI Pharmaceuticals, Inc. 12 U.S.-based manufacturing footprint; strong GMP track record, including successful FDA audits at all three sites • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, topicals, ta

  13. Slide 13: Executive Leadership Team with proven track records and broad industry expertise

    © 2023 ANI Pharmaceuticals, Inc. 13 Executive Leadership Team with proven track records and broad industry expertise ‒ 20+ years of legal and leadership experience in specialty and generics pharmaceuticals ‒ Served as Vice President and Associate GC for Amneal Pharmaceuticals ‒ Previously with Morga

  14. Slide 14: Investment summary

    © 2023 ANI Pharmaceuticals, Inc. 14 Robust and nimble Generics segment delivering growth • Demonstrated R&D excellence in filings and launch execution • Providing reliability of supply with US-based manufacturing and strong GMP track record Experienced purpose-driven team • Dedicated employees with

  15. Slide 15: ANI recently celebrated a decade since listing on the NASDAQ

    © 2023 ANI Pharmaceuticals, Inc. 15 ANI recently celebrated a decade since listing on the NASDAQ

  16. Slide 16: January 2024

    © 2023 ANI Pharmaceuticals, Inc. 16 January 2024

  17. Slide 17: Adjusted non-GAAP EBITDA calculation – 3Q 2023 and 2022

    © 2023 ANI Pharmaceuticals, Inc. 17 Adjusted non-GAAP EBITDA calculation – 3Q 2023 and 2022 (1) Impact of Canada operations includes CDMO revenues, cost of sales relating to CDMO revenues, all selling, general, and administrative expenses, and all research and development expenses recorded in Canada

  18. Slide 18: Adjusted non-GAAP EBITDA calculation – full year 2022 and 2021

    © 2023 ANI Pharmaceuticals, Inc. 18 Adjusted non-GAAP EBITDA calculation – full year 2022 and 2021 (1) Adjustment to other expense, net excludes $750K of income related to the sale of an ANDA during the three months ended December 31, 2021, and excludes $750K and $1.9 million of income related to th

ANI Pharmaceuticals — Investor Presentation (January 2024) on 6ix